|
elevator pitch script (60 seconds version and 30 seconds version) / 1. 60-second elevator pitch 2. 30-Second Elevator Pitch / 1. 60-second elevator pitch 60ÃÊ µ¿¾ÈÀÇ elevator pitch´Â ÀÚ½ÅÀÇ ¾ÆÀ̵ð¾î³ª »ç¾÷À» °£°áÇÏ°í ¸Å·ÂÀûÀ¸·Î ¼Ò°³ÇÏ´Â Áß¿äÇÑ ±âȸ´Ù. ÀÌ ÂªÀº ½Ã°£ ¾È¿¡ »ó´ë¹æÀÇ °ü½ÉÀ» ²ø°í ±â¾ï¿¡ ³²µµ·Ï ÇÏ´Â °ÍÀÌ ¸ñÇ¥´Ù. ÈǸ¢ÇÑ elevator pitch´Â µÎ °¡Áö ¡¦ |
|
·¹Æ÷Æ® >
±âŸ  | 
2p age   | 
3,000 ¿ø
|
|
|
|
|
|
1. Á¦¸ñ (Title) ¿ÀÆÛ¿¢ÇÁ ÁõÆø±â(Operational Amplifier, Op-Amp)´Â ÀüÀÚ°øÇп¡¼ Áß¿äÇÑ ±âº» ¼ÒÀÚ·Î, ´Ù¾çÇÑ ¾Æ.. / 1. Á¦¸ñ (Title) 2. ¼³°è ¸ñÀû (Purpose) 3. ¹è°æ Áö½Ä (Background knowledge) 4. ¼³°è¿Í ºÐ¼® (Design and Analysis) 5. ÅäÀÇ (Discussion) / 1. Á¦¸ñ (Title) ¿ÀÆÛ¿¢ÇÁ ÁõÆø±â(Operational Amplifier, Op-Amp)´Â ÀüÀÚ°øÇп¡¼ Áß¿äÇÑ ±âº» ¼ÒÀÚ·Î, ´Ù¾çÇÑ¡¦ |
|
|
|
|
|
1. Membrane blockingÀÌ ÇÊ¿äÇÑ ÀÌÀ¯ Membrane blockingÀÌ ÇÊ¿äÇÑ ÀÌÀ¯´Â ´Ù¾çÇÑ ½ÇÇè¿¡¼ ºñƯÀÌÀûÀÎ °áÇÕÀ» ¿¹¹æÇÏ°í.. / 1. Membrane blockingÀÌ ÇÊ¿äÇÑ ÀÌÀ¯ 2. blockingÀ» ¼öÇàÇϱâ À§ÇØ »ç¿ëÇÏ´Â ½Ã¾à 3. Western blot Ç×ü ¹ÝÀÀ ½Ã primary antibody¿Í secondary antibody·Î ±¸ºÐÇÏ¿© »ç¿ëÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡ 4. Âü°í¹®Çå / 1. Membrane blockingÀÌ ÇÊ¿äÇÑ ÀÌÀ¯ Membran¡¦ |
|
|
|
|
|
Secondary malignant neoplasm of liver and intrahepatic bile duct ÄÉÀ̽º ¸®Æ÷Æ® / 1. PBLÀ» ÅëÇÑ °£È£»ç·Ê 2. ¹®Çå°íÂû 3. Áø´Ü°Ë»ç 4. ¾à¹° 5. °£È£°úÁ¤ 6. °á·Ð 7. Reference 8. ½Ç½À¼Ò°¨¹® / 1. PBLÀ» ÅëÇÑ °£È£»ç·Ê °£È£»ç´Â ȯÀÚÀÇ Àü¹ÝÀûÀÎ °Ç° »óŸ¦ Æò°¡ÇÏ°í, Ä¡·á °úÁ¤¿¡¼ Á÷¸éÇÏ´Â ´Ù¾çÇÑ ¹®Á¦¸¦ ÀÌÇØÇÏ°í °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇØ¾ß ÇÑ´Ù. ƯÈ÷ °£¡¦ |
|
|
|
|
|
¾Ïº´µ¿ case study (bone tumor, secondary malignant neoplasm of bone) / 1. ¼·Ð (1) »ç·Ê¿¬±¸ÀÇ Çʿ伺 (2) ¹®Çå°íÂû 2. º»·Ð (1) °Ç°»çÁ¤ (2) Áø´Ü ¹× Ä¡·á (3) Ä¡·á°æ°ú ¹× °èȹ (4) °£È£Áø´Ü 3. °á·Ð / 1. ¼·Ð ¾Ïº´µ¿¿¡¼ÀÇ »ç·Ê ¿¬±¸´Â ȯÀÚÀÇ »ýÁ¸°ú Àü¹ÝÀûÀÎ »îÀÇ Áú Çâ»óÀ» ¸ñÇ¥·Î ÇÏ´Â Áß¿äÇÑ È°µ¿ÀÌ´Ù. ƯÈ÷ »À Á¾¾ç ¹× ÀÌÂ÷ ¾Ç¼ºÁ¾¾ç°ú °°Àº º¹ÀâÇÑ »ç·Ê´Â¡¦ |
|
|
|
|
|
Secondary metabolite¿¡ ´ëÇÑ ³»¿ë ÀÔ´Ï´Ù.( ±×·¡ÇÁ ÷ºÎ) ¹°ÁúºÐ¼® / PURPOSE ÀÌÂ÷ ´ë»ç»ê¹°À» ¾Ë°í HPLC¸¦ ÅëÇØ ¹°ÁúÀÇ À¯¹«¸¦ È®ÀÎÇÑ´Ù. Introduction 1. Lovastatin Monacolin K inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, and are effective in lowering plasma cholesterol levels in human as¡¦ |
|
|
|
|
|
6. SOAP note ÀÌÂ÷¼º ÆÄŲ½¼Áõ(secondary parkinsonism) ȯÀںР/ 1. Subjective information 2. Objective information 3. Assessment 4. Plan / 1. Subjective information ȯÀÚ´Â ÃÖ±Ù ¸î °³¿ù°£ Áõ»óÀÌ ¾ÇÈµÈ °ÍÀ¸·Î ´À³¢°í ÀÖ´Ù. óÀ½¿¡´Â °¡º¿î ¼Õ ¶³¸²ÀÌ ÀÖ¾ú°í, ƯÈ÷ ¿À¸¥ÂÊ ¼Õ¿¡¼ ´õ µÎµå·¯Á³´Ù. ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¼Õ ¶³¸²ÀÌ ½ÉÇØÁö°í, Á¡Â÷ ¿ÞÂÊ ¼Õ°ú ´Ù¸®·Îµµ ÆÛÁ³¡¦ |
|
|
|
|
|
6. SOAP note ÀÌÂ÷¼º ÆÄŲ½¼Áõ(secondary parkinsonism) ȯÀںР/ 1. Subjective information 2. Objective information 3. Assessment 4. Plan / 1. Subjective information ȯÀÚºÐÀº 60¼¼ ³²¼ºÀ¸·Î, ÃÖ±Ù ¸î °³¿ù°£ ÁÂÃø ¼ÕÀÇ ¶³¸²°ú °æÁ÷À» °æÇèÇÏ°í ÀÖ´Ù°í ÇÑ´Ù. óÀ½¿¡´Â ÀϽÃÀûÀÎ Áõ»óÀ¸·Î »ý°¢ÇßÁö¸¸ Á¡Â÷ Áõ»óÀÌ ½ÉÇØÁ³°í, ÀÏ»ó»ýÈ°¿¡ ¿µÇâÀ» ¹ÌÄ¡±â ½ÃÀÛÇß´Ù°í ÇÑ´Ù. ƯÈ÷¡¦ |
|
|
|
|
|
Secondary malignant neoplasm of liver and intrahepatic bile duct ÄÉÀ̽º ¸®Æ÷Æ® / 1. PBLÀ» ÅëÇÑ °£È£»ç·Ê 2. ¹®Çå°íÂû 3. Áø´Ü°Ë»ç 4. ¾à¹° 5. °£È£°úÁ¤ 6. °á·Ð 7. Reference 8. ½Ç½À¼Ò°¨¹® / 1. PBLÀ» ÅëÇÑ °£È£»ç·Ê PBLÀ» ÅëÇÑ °£È£»ç·Ê¿¡¼´Â °£ÀÇ ÀÌÂ÷ ¾Ç¼º ½Å»ý¹°°ú ´ã°ü ³» ¾Ç¼º ½Å»ý¹°ÀÇ »ç·Ê¸¦ ´Ù·ç°Ô µÈ´Ù. ÀÌ´Â ÁÖ·Î ´Ù¸¥ Àå±â¿¡¼ ¹ß»ýÇÑ ¾ÏÀÌ ÀüÀÌµÇ¾î °£°ú¡¦ |
|
|
|
|
|
¾Ïº´µ¿ case study (bone tumor, secondary malignant neoplasm of bone) / 1. ¼·Ð (1) »ç·Ê¿¬±¸ÀÇ Çʿ伺 (2) ¹®Çå°íÂû 2. º»·Ð (1) °Ç°»çÁ¤ (2) Áø´Ü ¹× Ä¡·á (3) Ä¡·á°æ°ú ¹× °èȹ (4) °£È£Áø´Ü 3. °á·Ð / 1. ¼·Ð ¾Ïº´µ¿¿¡¼ÀÇ ÄÉÀ̽º ½ºÅ͵ð´Â º¹ÀâÇÏ°í ´Ù¾çÇÑ È¯ÀÚ Äɾ Æ÷ÇÔÇϸç, ƯÈ÷ »À Á¾¾çÀ̳ª ÀüÀ̼º »À Á¾¾çÀÇ °æ¿ì ±× º¹À⼺ÀÌ ´õ¿í µÎµå·¯Áø´Ù. »À Á¾¾ç¡¦ |
|
|
|
|